Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma

NCT00623805 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00623805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
May 31, 2012
Enrollment
123 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer